---
category: news
title: "BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology"
excerpt: "Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in Phase 2 clinical trials NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,"
publishedDateTime: 2022-04-19T11:13:00Z
originalUrl: "https://www.tmcnet.com/usubmit/2022/04/19/9584732.htm"
webUrl: "https://www.tmcnet.com/usubmit/2022/04/19/9584732.htm"
type: article

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "0bK/zK+4VvLg6dSdQIhP55OcAfjJFpCW4VJTI7XZxGWkgNAWp0LHjWshTCyamPmh+RxI92qLsbxT5rST1fppVPpJCSrolEvEsXXkNZug9rAWWbpTJKO6iPsEKp2oAJTh7hjhIczXAAwkT82U/CnMkWgJl8LG0rAvceNQQZ4jSs7HsWBRa08uKJ1tsyiOqMr9n8mB2JemURnfR9JY4HdTxfNkmOsYNCghbd4EAJBB8L9OgeItn7p6NxeuxXDT2RDDUFZ6L8I+c+Tg85KjLerIzWCQy+ICQVnE9JvcR5nM7/CQhiohb10r5wftjn1IP5sLl2sdUjb9QSW7DOL9m8U8A6W0P0jpN32NhbD4ml5KEVs=;AnDhsb+AEsZYPeejW5quDA=="
---

